Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER)

Key Points

• Omeros Corporation (NASDAQ:OMER) experienced a significant increase in call options trading, with 3,697 call options purchased, representing a 422% rise compared to the typical volume.
• The company reported a quarterly loss with an EPS of ($0.65), missing expectations by ($0.05).
• Omeros has a current market cap of $220.01 million and a consensus rating of "Moderate Buy" from analysts, with an average price target of $18.00.
• Institutional investors collectively own 48.79% of Omeros's stock, highlighting strong institutional interest in the company.

Omeros Corporation (NASDAQ:OMER - Get Free Report) saw unusually large options trading activity on Friday. Stock traders bought 3,697 call options on the company. This is an increase of 422% compared to the average daily volume of 708 call options.

Omeros Stock Performance

Shares of NASDAQ OMER traded up $0.17 during trading on Friday, reaching $3.76. The company had a trading volume of 3,547,700 shares, compared to its average volume of 823,107. Omeros has a 52 week low of $2.95 and a 52 week high of $13.60. The stock has a market cap of $220.01 million, a PE ratio of -1.42 and a beta of 2.16. The business's 50 day moving average price is $3.35 and its 200-day moving average price is $6.36.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Equities analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OMER. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Omeros in a report on Friday, June 27th. D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Monday, June 30th. Finally, Wall Street Zen downgraded shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Institutional Investors Weigh In On Omeros

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its holdings in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP acquired a new position in Omeros during the fourth quarter worth $46,000. GAMMA Investing LLC raised its position in Omeros by 14,486.3% during the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,388 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in Omeros during the fourth quarter worth $83,000. Finally, Harbour Investments Inc. raised its position in Omeros by 51.9% during the first quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 3,149 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.